Media Update




Ipsen provides update on legacy of Henri
Beaufour

PARIS, FRANCE, 5 December 2025, Ipsen (Euronext: IPN; ADR: IPSEY) has been informed that the
shares of Beech Tree will be transferred to the Alasol Foundation, in accordance with the
wishes of Mr. Henri Beaufour, Ipsen’s Board Member and a representative of the founding
family who passed away on November 28, 2025. This transfer is expected to take place in
early 2026 after having obtained the required regulatory approvals*.

Beech Tree is the holding company owning directly and indirectly the stake in Ipsen shares of
Mr. Beaufour. Alasol Foundation is a public interest foundation created by Mr. Beaufour to
promote education, school and vocational training for disadvantaged children and young
adults.

This transfer of shares has no effect on the existing shareholders' agreement between Beech
Tree and Highrock.

About Ipsen
We are a global biopharmaceutical company with a focus on bringing transformative
medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.

Our pipeline is fueled by internal and external innovation and supported by nearly 100 years
of development experience and global hubs in the U.S., France and the U.K. Our teams in more
than 40 countries and our partnerships around the world enable us to bring medicines to
patients in more than 100 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American
Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.

Ipsen Contacts

Investors
Henry Wheeler henry.wheeler@ipsen.com +33 764471149
Khalid Deojee khalid.deojee@ipsen.com +33 666019526

Media
Sally Bain sally.bain@ipsen.com +1 8573200517
Anne Liontas anne.liontas.ext@ipsen.com +33 767347296

*According to a press release from Beech Tree.



1
Media Update



Disclaimers and/or forward-looking statements
The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current
views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results,
performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability
to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information
available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-
looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations.
Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and
potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded
as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on
historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties,
notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the
market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face
competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development
process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be
forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be
certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the
results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be
no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially
successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and healthcare legislation and risks arising from unexpected regulatory or
political changes such as changes in tax regulation and regulations on trade and tariffs, such as protectionist measures,
especially in the United States; global trends toward healthcare cost containment; technological advances, new medicine and
patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval;
Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for
innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on
third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners
could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its
partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s
partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business,
financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward
looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions
or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to
the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and
uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document,
available on ipsen.com.




2